Innate Pharma SA (OTCMKTS:IPHYF) Sees Large Growth in Short Interest

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 23,016 shares, a growth of ∞ from the April 30th total of 0 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 36 shares, the days-to-cover ratio is currently 639.3 days.

Innate Pharma Price Performance

Shares of OTCMKTS:IPHYF remained flat at $1.65 during trading on Tuesday. Innate Pharma has a 1 year low of $1.37 and a 1 year high of $2.25. The stock’s 50-day moving average price is $1.62 and its 200-day moving average price is $1.94.

About Innate Pharma

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.